Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)

WuXi Bi­o­log­ics seeks spin­out, HK list­ing of bio­con­ju­gates-fo­cused joint ven­ture

An­oth­er mem­ber of the WuXi AppTec fam­i­ly is set to be spun off and sep­a­rate­ly list­ed on the Hong Kong Stock Ex­change, al­low­ing the con­tract re­search, de­vel­op­ment and man­u­fac­tur­ing con­glom­er­ate to branch out even fur­ther.

The pro­posed list­ing would look to raise $500 mil­lion, the In­ter­na­tion­al Fi­nanc­ing Re­view re­ports.

WuXi XDC, the sub­sidiary in ques­tion, is a joint ven­ture be­tween WuXi Bi­o­log­ics — the Hong Kong-list­ed bi­o­log­ics-fo­cused arm — and WuXi STA, which spe­cial­izes in small mol­e­cules and pep­tides. Formed in June 2021, it of­fers con­tract ser­vices re­lat­ing to bio­con­ju­gates, in­clud­ing an­ti­body-drug con­ju­gates, pep­tide con­ju­gates, oli­go con­ju­gates and more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA